INT14048

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 1991
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 5.05
Pain Relevance 1.51

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (TKT) small molecule metabolic process (TKT) nucleolus (TKT)
peroxisome (TKT) nucleus (TKT) carbohydrate metabolic process (TKT)
Anatomy Link Frequency
brain 1
external 1
TKT (Homo sapiens)
Pain Link Frequency Relevance Heat
Kinase C 13 99.44 Very High Very High Very High
qutenza 3 98.36 Very High Very High Very High
Versed 6 95.84 Very High Very High Very High
adenocard 2 91.24 High High
ketamine 6 87.84 High High
Morphine 6 86.16 High High
Potency 1 59.20 Quite High
abdominal pain 2 48.72 Quite Low
Eae 1 40.00 Quite Low
cytokine 2 32.48 Quite Low
Disease Link Frequency Relevance Heat
Dementia 1 99.84 Very High Very High Very High
Disease 197 99.30 Very High Very High Very High
Lung Cancer 41 96.56 Very High Very High Very High
Alzheimer's Dementia 4 96.32 Very High Very High Very High
Shock 7 96.00 Very High Very High Very High
Cancer 221 94.72 High High
Metastasis 26 93.72 High High
Colon Cancer 5 93.28 High High
Non-small-cell Lung Cancer 154 90.96 High High
Gastrointestinal Stromal Tumor 208 90.68 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
TK inhibition attenuated (P < 0.05) both peak and sustained CCE.
Negative_regulation (inhibition) of TK
1) Confidence 0.34 Published 2008 Journal Am. J. Physiol. Lung Cell Mol. Physiol. Section Abstract Doc Link 18344413 Disease Relevance 0 Pain Relevance 0.71
The effects of PKC activation and inhibition, TK inhibition, and the intravenous anesthetics on CCE were assessed.
Negative_regulation (inhibition) of TK associated with kinase c
2) Confidence 0.29 Published 2008 Journal Am. J. Physiol. Lung Cell Mol. Physiol. Section Abstract Doc Link 18344413 Disease Relevance 0 Pain Relevance 0.51
TK depletion was performed via 5-day pretreatment of capsaicin, which began 11 days before the study.
Negative_regulation (depletion) of TK associated with qutenza
3) Confidence 0.15 Published 1991 Journal Exp. Lung Res. Section Abstract Doc Link 1685118 Disease Relevance 0 Pain Relevance 0.10
Following TK depletion, antigen challenge produced pulmonary changes similar to those without depletion.
Negative_regulation (depletion) of TK
4) Confidence 0.15 Published 1991 Journal Exp. Lung Res. Section Abstract Doc Link 1685118 Disease Relevance 0 Pain Relevance 0.08
Forty-five guinea pigs were randomly divided into six groups: control, antigen challenge, TK depletion + antigen challenge, ganglionic (Ggl) blockade, Ggl blockade + antigen challenge, and TK depletion + Ggl blockade + antigen challenge.
Negative_regulation (depletion) of TK
5) Confidence 0.15 Published 1991 Journal Exp. Lung Res. Section Abstract Doc Link 1685118 Disease Relevance 0 Pain Relevance 0.08
There are several methods of inhibiting the EGFR pathway including monoclonal EGFR antibodies and small molecule inhibitors of TK.
Negative_regulation (inhibitors) of TK
6) Confidence 0.13 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721286 Disease Relevance 0.33 Pain Relevance 0
There are several methods of EGFR inhibition including monoclonal antibodies directed against the external region and small molecule inhibitors of TK domain.
Negative_regulation (inhibitors) of TK in external
7) Confidence 0.10 Published 2007 Journal Biologics : Targets & Therapy Section Abstract Doc Link PMC2721286 Disease Relevance 0.81 Pain Relevance 0
A different method of blocking EGFR is by inhibiting the cytoplasmic TK domain.
Negative_regulation (inhibiting) of TK
8) Confidence 0.08 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721286 Disease Relevance 0.47 Pain Relevance 0
Vandetanib (ZD-6474) is a TK inhibitor of VEGFRR-2, VEGFR-3, Ret and EGFR (Ciardiello et al 2003) thus inhibiting both the VEGF dependent angiogenesis and EGFR dependent tumor cell proliferation.
Negative_regulation (inhibitor) of TK associated with cancer
9) Confidence 0.07 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 0.42 Pain Relevance 0.03
The activity of transketolase has been reported to be reduced in dementia of Alzheimer’s type brain (25).
Negative_regulation (reduced) of transketolase in brain associated with dementia
10) Confidence 0.04 Published 2003 Journal Biol Proced Online Section Body Doc Link PMC302190 Disease Relevance 1.45 Pain Relevance 0
Small-molecule EGFR TK inhibitors (TKIs) are competetive inhibitors and bind reversibly to the intracellular catalytic domain of EGFR tyrosine kinase and, thus, inhibit EGFR autophosphorylation and downstream signaling.
Negative_regulation (inhibitors) of TK
11) Confidence 0.03 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886327 Disease Relevance 0.23 Pain Relevance 0
When patients were followed by 18FDG-PET, metabolic response was noted as early as 7 days post-initiation of therapy, but this suppression was followed by a rebound during the 2-week-off period, suggesting a flare in disease activity, consistent with lack of TK inhibition during the wash-out period.43 In an attempt to provide consistent TK inhibition, and to enhance convenience of dosing, an international, multicenter phase II study using continuous daily dosing of sunitinib, at 37.5 mg/day, was undertaken to examine this issue.44 In this study, sixty-one patients with advanced GIST following imatinib failure were enrolled.
Negative_regulation (inhibition) of TK associated with disease and gastrointestinal stromal tumor
12) Confidence 0.03 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2819895 Disease Relevance 0.67 Pain Relevance 0
When patients were followed by 18FDG-PET, metabolic response was noted as early as 7 days post-initiation of therapy, but this suppression was followed by a rebound during the 2-week-off period, suggesting a flare in disease activity, consistent with lack of TK inhibition during the wash-out period.43 In an attempt to provide consistent TK inhibition, and to enhance convenience of dosing, an international, multicenter phase II study using continuous daily dosing of sunitinib, at 37.5 mg/day, was undertaken to examine this issue.44 In this study, sixty-one patients with advanced GIST following imatinib failure were enrolled.
Negative_regulation (inhibition) of TK associated with disease and gastrointestinal stromal tumor
13) Confidence 0.02 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2819895 Disease Relevance 0.67 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox